<DOC>
	<DOCNO>NCT00284258</DOCNO>
	<brief_summary>This study design Phase II/III . Phase II aim evaluate safety efficacy IRIS , feasibility FOLFIRI . Phase III aim verify inferiority progression free survival IRIS comparison FOLFIRI .</brief_summary>
	<brief_title>Phase II/III Trial CPT-11/5-FU/l-LV Versus CPT-11/TS-1 Second Line Chemotherapy Unresectable Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm colorectal cancer Locally advance and/or metastatic colorectal cancer Have prior chemotherapy first line treatment No prior irinotecan administration Able take oral medication Age 20 75 Performance status 0 1 ( ECOG ) WBC 3,00012,000 / mm^3 Platelet ≥100,000 / mm^3 AST ALT ≤ 100 IU/L Creatinine ≤ 1.2 mg/dL Bilirubin ≤ 1.5 mg/dL Prior radio therapy colorectal cancer Other malignancy past 5 year Serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Colorectal Cancer</keyword>
</DOC>